Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
CRCL
MCID: CRT084
MIFTS: 25

Creatinine Clearance Quantitative Trait Locus (CRCL)

Genes Tissues Related diseases Publications Drugs
Sources

Aliases & Classifications for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards integrated aliases for Creatinine Clearance Quantitative Trait Locus:

Name: Creatinine Clearance Quantitative Trait Locus 57
Creatinine Clearance Qtl 57 13
Crcl 57

External Ids:

OMIM® 57 607135
Sources

Summaries for Creatinine Clearance Quantitative Trait Locus

About this section
MalaCards based summary : Creatinine Clearance Quantitative Trait Locus, also known as creatinine clearance qtl, is related to rapidly involuting congenital hemangioma and glioblastoma. An important gene associated with Creatinine Clearance Quantitative Trait Locus is CRCL (Creatinine Clearance QTL). The drugs Rivaroxaban and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include kidney, heart and bone.

More information from OMIM: 607135
Sources

Related Diseases for Creatinine Clearance Quantitative Trait Locus

About this section

Diseases related to Creatinine Clearance Quantitative Trait Locus via text searches within MalaCards or GeneCards Suite gene sharing:

# Related Disease Score Top Affiliating Genes
1 rapidly involuting congenital hemangioma 10.2
2 glioblastoma 10.1
3 ataxia and polyneuropathy, adult-onset 9.9
4 protein-losing enteropathy 9.9
5 chagas disease 9.9
6 adenocarcinoma 9.9
7 mouth disease 9.9
8 pathologic nystagmus 9.9

Graphical network of the top 20 diseases related to Creatinine Clearance Quantitative Trait Locus:



Diseases related to Creatinine Clearance Quantitative Trait Locus
Sources

Symptoms & Phenotypes for Creatinine Clearance Quantitative Trait Locus

About this section

Clinical features from OMIM®:

607135 (Updated 05-Apr-2021)

Sources

Drugs & Therapeutics for Creatinine Clearance Quantitative Trait Locus

About this section

Drugs for Creatinine Clearance Quantitative Trait Locus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rivaroxaban Approved Phase 4 366789-02-8
2
Clopidogrel Approved Phase 4 113665-84-2, 120202-66-6 60606
3
Tinzaparin Approved Phase 4 9041-08-1, 9005-49-6 25244225
4
Vitamin K1 Approved, Investigational Phase 4 84-80-0 5284607
5
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
6
Ribavirin Approved Phase 4 36791-04-5 37542
7
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
8
Apixaban Approved Phase 4 503612-47-3 10182969
9
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
10
Edoxaban Approved Phase 4 480449-70-5
11
Warfarin Approved Phase 4 81-81-2 54678486 6691
12
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
13
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
14
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
15
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
16
Acetaminophen Approved Phase 4 103-90-2 1983
17
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
18
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
19
Hydrocodone Approved, Illicit, Investigational Phase 4 125-29-1 5284569
20
Morphine Approved, Investigational Phase 4 57-27-2 5288826
21
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
22
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
23
Ceftaroline fosamil Approved, Investigational Phase 4 229016-73-3
24
Daptomycin Approved, Investigational Phase 4 103060-53-3 16129629
25
Linezolid Approved, Investigational Phase 4 165800-03-3 441401
26
Vancomycin Approved Phase 4 1404-90-6 14969 441141
27
Ofloxacin Approved Phase 4 82419-36-1 4583
28
Fosfomycin Approved Phase 4 23155-02-4 446987
29
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
30
Menadione Approved, Nutraceutical Phase 4 58-27-5 4055
31 Menaquinone Investigational Phase 4 1182-68-9
32
Tenofovir Experimental, Investigational Phase 4 147127-20-6 464205
33
Dabigatran Investigational Phase 4 211914-51-1
34 Factor Xa Inhibitors Phase 4
35 Cyclooxygenase Inhibitors Phase 4
36 Purinergic P2Y Receptor Antagonists Phase 4
37 Anti-Inflammatory Agents, Non-Steroidal Phase 4
38 Vitamins Phase 4
39 Vitamin K Phase 4
40 naphthoquinone Phase 4
41 Reverse Transcriptase Inhibitors Phase 4
42 Anti-Retroviral Agents Phase 4
43 Antiviral Agents Phase 4
44 Anti-HIV Agents Phase 4
45 Platelet Aggregation Inhibitors Phase 4
46 Serine Proteinase Inhibitors Phase 4
47 Antithrombin III Phase 4
48 Antithrombins Phase 4
49 Psychotropic Drugs Phase 4
50 Excitatory Amino Acid Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 56)
# Name Status NCT ID Phase Drugs
1 A Pilot Study of Edoxaban in Patients With Non-Valvular Atrial Fibrillation and Left Atrial Appendage Closure Unknown status NCT03088072 Phase 4 Edoxaban;Aspirin and Clopidogrel;Aspirin and Warfarin
2 Rivaroxaban Once Daily Versus Dose-adjusted Vitamin K Antagonist on the Biomarkers in Acute Decompensated Heart Failure and Atrial Fibrillation (ROAD HF-AF) Unknown status NCT03490994 Phase 4 Rivaroxaban;Warfarin + LMWH
3 A Pilot Demonstration Project to Operationalize Pre-exposure Prophylaxis as Part of Combination HIV Prevention Among Men Who Have Sex With Men (MSM) and Transgender Women in Los Angeles County Completed NCT01781806 Phase 4 emtricitabine 200mg/tenofovir 300mg
4 Non-Randomized, Multicenter Study to Evaluate the Pharmacokinetics and Safety of Peginterferon Alfa-2a and Copegus Combination Therapy After Single and Multiple Doses in Patients With Chronic Hepatitis C and Moderate Renal Impairment, Severe Renal Impairment, or End-Stage Renal Disease Undergoing Hemodialysis Completed NCT02864199 Phase 4 Peginterferon alfa-2a;Ribavirin
5 FREEDOM COVID Anticoagulation Strategy Randomized Trial Recruiting NCT04512079 Phase 4 Enoxaparin;Apixaban
6 A Multi-centre, Open-labelled, Randomized Controlled Trial Comparing Two Different Anticoagulation Strategies in High-risk Atrial Fibrillation and Stable Coronary Artery Disease Recruiting NCT03718559 Phase 4 Edoxaban;Single Antiplatelet Agents
7 Impact of Anticoagulation Therapy on the Cognitive Decline and Dementia in Patients With Non-Valvular Atrial Fibrillation (CAF Trial) Active, not recruiting NCT03061006 Phase 4 Dabigatran Etexilate;Warfarin
8 Pregabalin vs. Gabapentin on Reducing Opioid Usage in Orthopedic Trauma Patients Not yet recruiting NCT04705480 Phase 4 Pregabalin 50mg;Gabapentin 300mg;Neither Pregabalin nor Gabapentin
9 Evaluation of Intravenous Glucocorticoid Therapy in Total Knee Arthroplasty Suspended NCT02219581 Phase 4 Dexamethasone 10 mg;Dexamethasone 20 mg;Standard multimodal pain management regimen;Placebo
10 Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Terminated NCT01734694 Phase 4 Vancomycin;Ceftaroline;Daptomycin;Linezolid
11 Multi-center, Randomized, Open-label Trial to Evaluate the Efficacy of Oral Fosfomycin Versus Oral Levofloxacin Strategies in Complicated Urinary Tract Infections (FOCUS) Terminated NCT03697993 Phase 4 Fosfomycin tromethamine;Levofloxacin
12 Phase IV Study of the Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-Economic Comparison of Daptomycin vs Vancomycin Based Regimens Terminated NCT01133600 Phase 4 Cubicin;Vancomycin
13 Evaluation of the Efficacy and Safety of Rivaroxaban (BAY59-7939) for the Prevention of Stroke and Non-central Nervous System Systemic Embolism in Subjects With Non-valvular Atrial Fibrillation Completed NCT00494871 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Warfarin;Rivaroxaban placebo;Warfarin placebo
14 A Phase 3, Multicenter, Double-blind, Randomized, Active-controlled Clinical Study to Evaluate the Efficacy and Safety of Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem in Chinese Participants With Complicated Intra-abdominal Infection Completed NCT03830333 Phase 3 Ceftolozane/Tazobactam;Metronidazole;Meropenem;Placebo
15 International Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of KIACTA in Preventing Renal Function Decline in Patients With AA Amyloidosis Completed NCT01215747 Phase 3 KIACTA (eprodisate disodium);Placebo
16 A Phase 3, Multicenter, Randomized, Openlabel, Parallel-Group Study of the Efficacy and Safety of Lenalidomide (Revlimid®) Versus Chlorambucil as First-Line Therapy for Previously Untreated Elderly Patients With B-Cell Chronic Lymphocytic Leukemia (The Origin Trial) Completed NCT00910910 Phase 3 Lenalidomide;Chlorambucil
17 An Open-label, International, Multicenter, Interventional Study Exploring the Efficacy of Once-daily Oral Rivaroxaban (BAY 59-7939) for the Treatment of Left Atrial/Left Atrial Appendage Thrombus in Subjects With Nonvalvular Atrial Fibrillation or Atrial Flutter Completed NCT01839357 Phase 3 Rivaroxaban (Xarelto, BAY59-7939)
18 Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients Completed NCT00090766 Phase 2, Phase 3 valganciclovir [Valcyte]
19 A Prospective, Randomized, Open-label, Parallel-group, Active-controlled, Multicenter Study Exploring the Efficacy and Safety of Once-daily Oral Rivaroxaban (BAY59-7939) Compared With That of Dose-adjusted Oral Vitamin K Antagonists (VKA) for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion Completed NCT01674647 Phase 3 Rivaroxaban (Xarelto, BAY59-7939);Vitamin K antagonist (VKA)
20 Effects of Fenofibrate Administration in Patients With Diabetic Nephropathy Recruiting NCT03869931 Phase 3 Fenofibrate
21 Non-vitamin K Antagonist Oral Anticoagulants in Patients With Atrial High Rate Episodes - An Investigator-driven, Prospective, Randomised, Double-blind, Multi-centre Trial Initiated by the European Society of Cardiology and AFNET Recruiting NCT02618577 Phase 3 Edoxaban;ASA
22 Apixaban Versus Warfarin in Patients With Left Ventricular (LV) Thrombus Recruiting NCT03232398 Phase 3 Apixaban Oral Tablet [Eliquis];Warfarin
23 Colchicine for the Treatment of Cardiac Injury in Hospitalized Patients With COVID-19 (COLHEART-19) Suspended NCT04510038 Phase 2, Phase 3 Colchicine
24 A Randomized Trial of Anticoagulation Strategies in COVID-19 Terminated NCT04359277 Phase 3 Enoxaparin Higher Dose;Lower-dose prophylactic anticoagulation
25 A Phase IIb Trial of Vorinostat in Combination With Lenalidomide and Dexamethasone in Multiple Myeloma Patients Refractory to Previous Lenalidomide Containing Regimens Unknown status NCT01502085 Phase 1, Phase 2 Vorinostat, Lenalinomide and Dexamethasone
26 Phase II Study of the Combination of Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis Completed NCT01222260 Phase 2 Bendamustine;Dexamethasone
27 A Multicenter, Double-blind, Randomized, Clinical Study to Assess the Efficacy and Safety of Intravenous S-649266 in Complicated Urinary Tract Infections With or Without Pyelonephritis or Acute Uncomplicated Pyelonephritis Caused by Gram-Negative Pathogens in Hospitalized Adults in Comparison With Intravenous Imipenem/Cilastatin Completed NCT02321800 Phase 2 Cefiderocol;Imipenem/cilastatin
28 Phase IIA Clinical Study Of An Individualized Anti-Cancer Vaccine (CRCL-ALLOVAX) in Subjects With Advanced Hepatocellular Carcinoma Completed NCT02409524 Phase 2
29 Low Intensity Allogeneic Hematopoietic Stem Cell Transplantation Therapy of Metastatic Renal Cell Carcinoma Using Early and Multiple Donor Lymphocyte Infusions Consisting of Sirolimus-Generated Donor Th2 Cells Completed NCT00923845 Phase 2 Pentostatin;Sirolimus;Cyclophosphamide
30 Phase II Study Designed To Evaluate Safety and Tumor Debulking Mechanism of an Individualized Cancer Vaccine (AllovaxTM) in Patients With Metastatic or Recurrent Cancer of the Head and Neck. Completed NCT01998542 Phase 2
31 A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalidomide, and Dexamethasone in Elderly Newly Diagnosed Multiple Myeloma Patients Recruiting NCT04052880 Phase 2 Daratumumab;Bortezomib;Lenalidomide;Dexamethasone;Ixazomib
32 Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations Recruiting NCT03448718 Phase 2 Olaparib
33 Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation Recruiting NCT03159702 Phase 2 Evomela;Fludarabine
34 Efficacy of Tyrosine Kinase Inhibition in Reducing Eosinophilia in Patients With Myeloid and/or Steroid-Refractory Hypereosinophilic Syndrome Recruiting NCT00044304 Phase 2 Imatinib;Ruxolitinib
35 Open-label (Unblinded) Randomization to Treatment of Colchicine Plus Current Care Per Institution Treating Physicians vs. Current Care Per Institution Treating Physicians (Control Arm) Recruiting NCT04762771 Phase 1, Phase 2 Colchicine
36 Multicentre, Prospective Randomized Open Label, Blinded-endpoint (PROBE) Controlled Trial of Early Anticoagulation With Rivaroxaban Versus Standard of Care in Determining Safety at 365 Days in Symptomatic Cerebral Venous Thrombosis Recruiting NCT03178864 Phase 2 Rivaroxaban;Standard of care
37 Combination Chemotherapy (Methotrexate, L-asparaginase, Idarubicin and Dexamethasone) in Patients With Newly Diagnosed Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Recruiting NCT03599960 Phase 2 Chemotherapy
38 Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
39 Phase II Trial Investigating Tailoring First-Line Therapy For Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma Based on Mid-Treatment Positron Emission Tomography (PET) Scan Results Active, not recruiting NCT00324467 Phase 2 Cyclophosphamide;Doxorubicin;Vincristine;Prednisone;Ondansetron;Dexamethasone;Diphenhydramine;Acetaminophen;Ifosfamide;Mesna (IV);Mesna (oral);Carboplatin;Etoposide;Rituximab;Ondansetron;Dexamethasone;Diphenhydramine;Acetaminophen
40 Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial Active, not recruiting NCT01497496 Phase 2 High Dose Methylprednisolone (HDMP);Ofatumumab;Lenalidomide
41 A Non-Randomized Phase Ib-II Protocol of Paclitaxel, Carboplatin and the Dual PI3K/mTOR Kinase Inhibitor, PF-05212384, for Patients With Advanced, or Metastatic Non-Small Cell Carcinoma of the Lung Terminated NCT02920450 Phase 1, Phase 2 Gedatolisib;Paclitaxel;Carboplatin
42 Partially HLA Mismatched (Haploidentical) Allogeneic Bone Marrow Transplantation for Patients With Hematologic Malignancies Terminated NCT01749293 Phase 2 Fludarabine;Busulfan;Cyclophosphamide
43 Phase I Dose Escalation Trial of High Dose Melphalan Conditioning Regimen With Palifermin for Cytoprotection Followed by Autologous Peripheral Blood Stem Cell Transplantation for Multiple Myeloma Completed NCT00482846 Phase 1 melphalan
44 Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source Completed NCT02167958 Phase 1 Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolate;G-CSF
45 A Phase 1b Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone (DRd) in Japanese Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation Completed NCT02918331 Phase 1 Daratumumab (16 mg/kg);Lenalidomide;Dexamethasone
46 Evaluation of Serum Concentrations of Budesonide in Patients Treated for Gastrointestinal Graft-Versus-Host Disease and the Potential Interaction With Fluconazole or Voriconazole Terminated NCT01950507 Phase 1 Budesonide;Fluconazole;Voriconazole;Micafungin
47 Natural Course for Renal Function After Heart Transplantation Unknown status NCT02541981
48 How to Dose a Patient According to Renal Function? Glomerular Filtration Rate (GFR) or Creatinine Clearance (ClCr) Unknown status NCT02206373
49 Multi-center、Randomize、Open、Non-inferiority Study of Prophylactic Effect of Rivaroxaban on Venous Thromboembolism in AECOPD Unknown status NCT03277001 Rivaroxaban;Enoxaparin
50 Aggressive Hydration in Patients With ST-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention to Prevent Contrast-Induced Nephropathy, A Randomized, Controlled Trial REduction of riSk of Contrast-Induced Nephropathy followINg carDiac Catheterization 1 Unknown status NCT02067195 Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride);3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)

Search NIH Clinical Center for Creatinine Clearance Quantitative Trait Locus

Sources

Genetic Tests for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Anatomical Context for Creatinine Clearance Quantitative Trait Locus

About this section

MalaCards organs/tissues related to Creatinine Clearance Quantitative Trait Locus:

40
Kidney, Heart, Bone, Liver, Bone Marrow, Spinal Cord, Myeloid
Sources

Publications for Creatinine Clearance Quantitative Trait Locus

About this section

Articles related to Creatinine Clearance Quantitative Trait Locus:

(show top 50) (show all 1595)
# Title Authors PMID Year
1
A genome scan for renal function among hypertensives: the HyperGEN study. 57
11115379 2001
2
Potential Ameliorative Effects of Chromium Supplementation on Glucose Metabolism, Obesity, and Genomic Stability in Prediabetic Rat Model. 61
32710349 2021
3
Predictors of increased melphalan exposure correlate with overall survival, nonrelapse mortality, and toxicities in patients undergoing reduced-intensity allogeneic stem cell transplantation with fludarabine and melphalan. 61
32493164 2021
4
A case series of confusional states and other neurotoxic effects caused by ertapenem. 61
33010054 2021
5
Population pharmacokinetic and optimization of polymyxin B dosing in adult patients with various renal functions. 61
33002196 2021
6
Comparison of a thymine challenge test and endogenous uracil-dihydrouracil levels for assessment of fluoropyrimidine toxicity risk. 61
33687515 2021
7
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II). 61
33786798 2021
8
Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches. 61
33526481 2021
9
Ischemic stroke, hemorrhage, and mortality in patients with non-valvular atrial fibrillation and renal dysfunction treated with rivaroxaban: sub-analysis of the EXPAND study. 61
33728513 2021
10
Evaluation of glomerular filtration rate using iohexol plasma clearance in critically ill patients with augmented renal creatinine clearance: A single-centre retrospective study. 61
33742973 2021
11
Alendronate use in older patients with reduced renal function: challenges and opportunities in clinical practice. 61
33721033 2021
12
Renal function in children with a congenital solitary functioning kidney: A systematic review. 61
33752977 2021
13
Magnetic Exchange Field Modulation of Quantum Hall Ferromagnetism in 2D van der Waals CrCl3/Graphene Heterostructures. 61
33595292 2021
14
Synthesis and Characterization of Two "Tied-Back" Lithium Ketimides and Isolation of a Ketimide-Bridged [Cr2]6+ Dimer with Strong Antiferromagnetic Coupling. 61
33764048 2021
15
Blood pressure monitoring in kidney transplantation: a systematic review on hypertension and target organ damage. 61
33764450 2021
16
Safety of Intravenous Bisphosphonates for the Treatment of Hypercalcemia in Patients With Preexisting Renal Dysfunction. 61
32847379 2021
17
Two-Coordinate, Nonlinear Vanadium(II) and Chromium(II) Complexes of the Silylamide Ligand-N(SiMePh2)2: Characterization and Confirmation of Orbitally Quenched Magnetic Moments in Complexes with Sub-d5 Electron Configurations. 61
33621467 2021
18
Syntheses and solid-state structures of two cofacial (bis)dipyrrin dichromium complexes in different charge states. 61
33664167 2021
19
Conversion to everolimus in pediatric heart transplant recipients is a safe treatment option with an impact on cardiac allograft vasculopathy and renal function. 61
33315277 2021
20
Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study. 61
33560384 2021
21
Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. 61
33563634 2021
22
Acute Kidney Injury During Hospitalization Increases the Risk of VTE. 61
33031830 2021
23
Assessment of estimated glomerular filtration rate based on cystatin C in diabetic nephropathy. 61
33599678 2021
24
Relationship between the degree of renal dysfunction and the safety and efficacy outcomes in patients with atrial fibrillation receiving direct oral anticoagulants. 61
33664890 2021
25
Replacement of the Common Chromium Source CrCl3(thf)3 with Well-Defined [CrCl2(μ-Cl)(thf)2]2. 61
33671782 2021
26
Pharmacokinetics and Pharmacodynamics of Ceftolozane/Tazobactam in Critically Ill Patients With Augmented Renal Clearance. 61
33567333 2021
27
Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Analyses of Cefiderocol, a Parenteral Siderophore Cephalosporin, in Patients with Pneumonia, Bloodstream Infection/Sepsis, or Complicated Urinary Tract Infection. 61
33257454 2021
28
Radical Carbonyl Propargylation by Dual Catalysis. 61
33022838 2021
29
[Renal function performance in CKD stage 5: a sealed fate?] 61
33599425 2021
30
Population pharmacokinetics of ciprofloxacin in Pakistani patients suffering from enteric fever. 61
33026316 2021
31
Population pharmacokinetics of meropenem among post-operative patients in Pakistan. 61
33480841 2021
32
Anticoagulation Prescription and Outcomes in Relation to Renal Function in Patients with Atrial Fibrillation: Results from GLORIA-AF. 61
33564743 2021
33
Efficacy and safety of urate-lowering therapy in people with kidney impairment: a GCAN-initiated literature review. 61
33521512 2021
34
Chromium-Catalyzed Selective Dimerization/Hydroboration of Allenes to Access Boryl-Functionalized Skipped (E,Z)-Dienes. 61
33027539 2021
35
A Novel Creatinine-Based Equation to Estimate Glomerular Filtration Rate in Chinese Population With Chronic Kidney Disease: Implications for DOACs Dosing in Atrial Fibrillation Patients. 61
33679397 2021
36
Observation of Standing Spin Waves in a van der Waals Magnetic Material. 61
33244778 2021
37
Properties and dynamics of meron topological spin textures in the two-dimensional magnet CrCl3. 61
33420050 2021
38
Population pharmacokinetics of colistin and the relation to survival in critically ill patients infected with colistin susceptible and carbapenem-resistant bacteria. 61
32213316 2020
39
Population Pharmacokinetic Modeling of Vancomycin in Thai Patients With Heterogeneous and Unstable Renal Function. 61
32947558 2020
40
Clinical Characteristics Associated With Higher Enoxaparin Dosing Requirements for Venous Thromboembolism Prophylaxis in Trauma Patients. 61
33342267 2020
41
Hybrid System of Flocculation-Photocatalysis for the Decolorization of Crystal Violet, Reactive Red X-3B, and Acid Orange II Dye. 61
33324822 2020
42
Phytochemical Profile, Antioxidant, Cardioprotective and Nephroprotective Activity of Romanian Chicory Extract. 61
33396775 2020
43
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. 61
32969597 2020
44
Gilteritinib administration in a hemodialysis patient. 61
33175659 2020
45
Unifying Molecular Weights of Highly Linear Polyethylene Waxes through Unsymmetrical 2,4-Bis(imino)pyridylchromium Chlorides. 61
33261135 2020
46
Predictors of Bleeding in Patients Receiving Direct Oral Anticoagulants. 61
33197139 2020
47
A2AgCrCl6 (A = Li, Na, K, Rb, Cs) halide double perovskites: a transition metal-based semiconducting material series with appreciable optical characteristics. 61
33063074 2020
48
Computed Tomography Parameters and Estimated Glomerular Filtration Rate Formulas for Peridonation Living Kidney Donor Assessment. 61
32505497 2020
49
Which Trauma Patients Require Lower Enoxaparin Dosing for Venous Thromboembolism Prophylaxis? 61
33155833 2020
50
Strong In-Plane Magnetic Field-Induced Reemergent Superconductivity in the van der Waals Heterointerface of NbSe2 and CrCl3. 61
33058667 2020
Sources

Variations for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Expression for Creatinine Clearance Quantitative Trait Locus

About this section
Search GEO for disease gene expression data for Creatinine Clearance Quantitative Trait Locus.
Sources

Pathways for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

GO Terms for Creatinine Clearance Quantitative Trait Locus

About this section
Sources

Sources for Creatinine Clearance Quantitative Trait Locus

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....